Director, Marketing - Thought Leader Engagement Strategy

San Diego, CA (On-site)

$234K/yr – $262K/yrDirector/Executive8+ years expFull time

Posted 9 days ago

Job Summary

Own and drive the OL engagement strategy across speaker programs, advisory boards, KOL engagement, and cross-functional partnerships to deliver physician education and strategic insights that inform commercial decisions.

  • Own speaker bureau strategy and program effectiveness
  • Partner across Commercial, Medical Affairs, and Sales to align engagement plans

Job Description

Responsibilities

  • Develop and execute the overall OL engagement strategy in alignment with brand objectives and customer needs.
  • Identify emerging trends in HCP engagement and implement new models that enhance physician education, interaction, and experience.
  • Partner closely with Field Regional Marketing, Medical Affairs, Sales, Market Access, Commercial Operations, and Corporate Communications to ensure coordinated customer engagement strategies.
  • Create and maintain national and regional thought leader segmentation frameworks.
  • Develop annual and quarterly engagement plans aligned with brand objectives.
  • Build influence maps that identify key networks, referral patterns, and centers of excellence.
  • Continuously assess evolving stakeholder landscapes and emerging thought leaders.
  • Design and execute advocacy development strategies for priority thought leaders.
  • Establish advocacy goals and progression plans for key OLs.
  • Develop strategies to engage neutral or competitive physicians.

Requirements

  • Bachelor's degree required; advanced degree (MBA, PharmD, PhD, MPH, or equivalent) preferred.
  • 8+ years of biotechnology or pharmaceutical industry experience with significant oncology marketing experience; hematology experience strongly preferred.
  • Demonstrated experience leading OL engagement initiatives, including speaker programs, advisory boards, KOL engagement, and congress activities.
  • Proven ability to develop and execute strategic customer engagement plans in regulated environment
  • Skilled at transforming observations into business decisions.
  • Proven ability to operate in a fast paced, dynamic environment of a fully integrated biotech company, driving ideas with a focus on innovation and patient centricity.
  • Strong cross-functional leadership skills with experience partnering across Commercial, Medical Affairs, Sales, Regulatory, Legal, and Compliance.
  • Comfortable influencing without direct authority.
  • Excellent communication, presentation, and relationship-building skills.
  • Experience managing external agencies and vendors.

Preferred

  • AML and/or hematologic malignancy experience.
  • Oncology product launch experience.
  • Experience developing innovative physician engagement approaches beyond traditional speaker programs.
  • Experience leveraging digital and omnichannel channels to enhance HCP engagement.
  • Sales experience or strong partnership with field sales organizations.

Benefits

  • Career advancement/ development opportunities
  • Competitive comp package
  • Bonus
  • 401K + Employer contributions
  • Generous stock options
  • ESPP Plan
  • 20 days of PTO to start
  • 18 Holidays (Including Summer & Winter Break)
  • Generous Benefits Package with a variety of plans available with a substantial employer match
  • Paid Paternity/Maternity Leave
Kura Oncology logo

Kura Oncology

3.4 Glassdoor

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.

Founded in 2014
San Diego, California, USA
309 employees (21 in marketing)
60% recommend to a friend

Salaries

Posted range

$234K/yr – $262K/yr

Taken straight from the job posting.

See all Kura Oncology salaries

Marketing Team

Marketing Team Size
21 (7% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$1.2B
Last Raise
$150M
Post IPO Equity, 2 years ago

Funding History

  • Jan 2024
    Post IPO Equity • $150M
  • Jun 2023
    Post IPO Equity • $100M
  • Nov 2022
    Post IPO Equity • $25M

Traffic Signals

Monthly Visitors
15.7K
Monthly Google Ads Budget
$40
Traffic Source Mix
Search
45.8%
Direct
39.4%
Referral
6.9%
Social
6.4%
Paid
1.3%

Headcount Trend

Current headcount: ~311

Recent News

Kura Oncology logo

Director, Marketing - Thought Leader Engagement Strategy

Kura Oncology · San Diego, CA · On-site